MedPath

The AGOG (Australian Genomics and Clinical Outcomes of Glioma) Epidemiology Study - investigating lifestyle and environmental exposures and genetic variants and glioma risk in those with and without glioma.

Not Applicable
Recruiting
Conditions
Glioma
Cancer - Brain
Registration Number
ACTRN12615001182583
Lead Sponsor
Cancer Council Australia
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
1600
Inclusion Criteria

Case:
1. aged 18 to 79 years
2. diagnosed with glioma (including low and high grade glioma) between January 2013 and December 2016 with histopathological confirmation.
Control:
1. Aged of 18 and over the age of 79.
2. Never been diagnosed with glioma

Exclusion Criteria

Case
1.Non-residents of Australia.
2.Patients who are unable to provide written informed consent, or who are deemed by their clinician to be significantly cognitively impaired, and who do not have a person responsible to provide substitute consent on their behalf.
3.Patients who are unable to complete the questionnaires themselves in English.
4.Patients under the age of 18 and over the age of 79.
Control
1. Individuals who are unable to complete the questionnaires themselves in English.
2. Individuals under the age of 18 and over the age of 79.
3. Have been diagnosed with glioma

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ifestyle risk factors for glioma, assessed by the AGOG Epidemiology Study Participant Health and Lifestyle Questionnaire which was designed specifically for this study.<br>[Participants complete three questionnaires once upon enrolment. ];Genetic risk of glioma, assessed using a family history of cancer questionnaire (designed specifically for this study) and genetic data from a blood or saliva sample sample.<br>[DNA samples are collected once upon enrolment.. ];Collect histopathological reports at consent from recruiting doctor to collect archival tissue to identify new prognostic factors.[At participant consent.]
Secondary Outcome Measures
NameTimeMethod
il[Nil]
© Copyright 2025. All Rights Reserved by MedPath